Alkermes plc Overview
Pro stress-test →Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company's commercial business generated more than $1.4 billion in total revenues in 2025, alongside strong cash flow and profitability.
Strategic Profile
Pro stress-test →Alkermes is emphasizing a profitable commercial foundation, the advancement of its lead orexin 2 receptor agonist candidate ALKS 2680 into Phase 3 testing, and an expanding pipeline intended to broaden the company's footprint in neuroscience. The company completed its acquisition of Avadel, accelerating entry into the sleep medicine market with LUMRYZ, an FDA-approved product.
Competitive Landscape
Pro stress-test →Alkermes competes in neuroscience pharmaceuticals with commercial products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline for neurological disorders including narcolepsy and idiopathic hypersomnia. Primary competitors include large-cap pharma with established CNS portfolios (Eli Lilly, AbbVie/Allergan) and specialized sleep medicine companies (Avadel pre-acquisition, Jazz Pharmaceuticals).
Industry Context
Alkermes plc operates in Biopharmaceuticals - Neuroscience.
Key facts
Founded: 1987 · Headquarters: Dublin, Ireland · Revenue: $1.4B+ · Market cap: $2-10B (mid-cap range)